Liu et al. Breast Cancer Research (2017) 19:5
DOI 10.1186/s13058-017-0800-2

Breast Cancer Research

ERRATUM

Open Access

Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells

Chun-Yu Liu[1,2,3,4†], Ling-Ming Tseng[2,5†], Jung-Chen Su[1], Kung-Chi Chang[1,3,4], Pei-Yi Chu[6], Wei-Tien Tai[7,8], Chung-Wai Shiau[1*] and Kuen-Feng Chen[7,8*]

Erratum

In the published article [1], the authors noticed an error to Fig. 1e in which the MTT curve of drug treatments (sorafenib, SC-1 and SC-43) in SK-BR3 cells was erroneously put as the same with that of HCC-1937 cells.

The correct version of Fig. 1 (including correct Fig. 1e) is included in this erratum.

Author details
[1]Institute of Biopharmaceutical Sciences, National Yang-Ming University, No. 155 Sec. 2, Li-Nong Street, Taipei 112, Taiwan. [2]School of Medicine, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan. [3]Division of Hematology and Oncology, Taipei Veterans General Hospital, No 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan. [4]Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan. [5]Department of Surgery, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan. [6]Department of Pathology, St. Martin De Porres Hospital, No. 565, Sec. 2, Daya Road, Chiayi 600, Taiwan. [7]Department of Medical Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. [8]National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan.

Received: 3 January 2017 Accepted: 3 January 2017
Published online: 11 January 2017

Reference

1. Liu CY, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013;15:R63. doi:10.1186/bcr3457.

* Correspondence: cwshiau@ym.edu.tw; kfchen1970@ntu.edu.tw
†Equal contributors
[1]Institute of Biopharmaceutical Sciences, National Yang-Ming University, No. 155 Sec. 2, Li-Nong Street, Taipei 112, Taiwan
[7]Department of Medical Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan



Fig. 1 SC-1 and SC-43, without effects on raf-1 kinase activity, show more potent anti-proliferative activity than sorafenib in breast cancer cells. **a** chemical structures of sorafenib, SC-1 and SC-43. **b** effects of sorafenib, SC-1 and SC-43 on Raf-1 activity in MDA-MB-231 cells. Columns, mean (n = 3); bars, SD; *P <0.05 compared to control. **c** effects of sorafenib, SC-1 and SC-43 on the phosphorylation of ERK1/2, VEGFR2 and PDGFRβ in MDA-MB-231cells. Cells were exposed to sorafenib, SC-1 or SC-43 at 1 and 5 μM for 12 hours. Data are representative of three independent experiments. **d** effects of sorafenib, SC-1 and SC-43 on the phosphorylation of STAT3 upstream kinases JAK1 and JAK2 in MDA-MB-231 (Left) and MDA-MB-468 cells (Right). Cells were exposed to sorafenib, SC-1 or SC-43 at 1 and 5 μM for 12 hours. Data are representative of three independent experiments. **e** dose-escalation effects of sorafenib, SC-1 and SC-43 on cell viability in six breast cancer cell lines. Cells were exposed to sorafenib, SC-1 or SC-43 at the indicated doses for 48 hours and cell viability was assessed by the MTT assay. Points, mean (n = 3); bars, SD. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide